Pfizer Gains Option to Acquire Gene Therapy Specialist Vivet Therapeutics

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 3 (Table of Contents)

Published: 27 Mar-2019

DOI: 10.3833/pdr.v2019.i3.2413     ISSN: 1756-7874

Section: Research & Development



Following in the footsteps of Biogen and Roche, Pfizer has acquired a 15% equity interest in gene therapy specialist, Vivet Therapeutics, with an option to acquire the company following the release of Phase I/II clinical trial data for VTX-801...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details